Lipella pharmaceuticals issues letter from the ceo to stockholders following nasdaq delisting

Pittsburgh, june 25, 2025 (globe newswire) -- lipella pharmaceuticals inc. (otc: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from chief executive officer jonathan kaufman to stockholders. the letter provides detailed responses to frequently asked questions regarding the company's recent delisting from the nasdaq capital market, as well as insight into lipella's clinical programs, financial position, and plans to relist on a national exchange.
LIPO Ratings Summary
LIPO Quant Ranking